The latest update on Laurus Labs keeps the existing price target unchanged, with no revisions from analysts at this point.

We visited a manufacturing plant of Laurus and interacted with management on various aspects of its key segments – CDMO and generics formulations. Laurus is witnessing a strong scale-up in CDMO ...

Sai's management reiterated long-term guidance of 15-20 per cent revenue CAGR with 28-30 per cent steady state EBITDA margin ...

Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 5 June 2026 - BSE, Laurus Labs and Exide ...

Laurus Labs Ltd. broke out from a five-month consolidation on monthly charts, reaching fresh record highs in May. Experts suggest short-term traders can buy the stock for a target of Rs 1300 in the ...

LAURUSLABS surged on June 1. The stock opened at Rs 334.65, up over 2 per cent from its Wednesday's close of Rs 330.7 on the ...

As of 10:37 a.m., shares of Laurus Labs traded 7.14 per cent, or Rs 28.45, lower on the BSE at Rs 370.1 apiece. The market ...

Chandan Taparia, head of technical and derivatives research at Motilal Oswal Financial Services Ltd., has recommended three stocks for investors to buy. These stocks are Laurus Labs Ltd., Apollo ...

In a report released today, Alok Dalal from Jefferies maintained a Hold rating on Laurus Labs Ltd., with a price target of INR1,100.00. Dalal covers the Healthcare sector, focusing on stocks such as ...

Laurus Lab delivered in-line revenue in 4QFY26. Improved operating leverage led to a 7% beat on EBITDA. A lower-than-expected tax rate led to 19% beat on PAT for the quarter. FY26 is the second ...